Related references
Note: Only part of the references are listed.Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence
Miranda J. Payne et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
Michal J. Besser et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Laszlo G. Radvanyi et al.
CLINICAL CANCER RESEARCH (2012)
Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
Richard W. Joseph et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
Ester Simeone et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Jane L. Messina et al.
SCIENTIFIC REPORTS (2012)
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Amod A. Samaik et al.
CLINICAL CANCER RESEARCH (2011)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs et al.
CLINICAL CANCER RESEARCH (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Science gone translational: the OX40 agonist story
Andrew D. Weinberg et al.
IMMUNOLOGICAL REVIEWS (2011)
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hemon et al.
JOURNAL OF IMMUNOLOGY (2011)
Intra-lesional Interleukin-2 for the Treatment of In-Transit Melanoma
Kirsty U. Boyd et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know
Steven A. Rosenberg
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study
P. Quaglino et al.
ANNALS OF ONCOLOGY (2010)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Michal J. Besser et al.
CLINICAL CANCER RESEARCH (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Immunotherapy for Melanoma: Current Status and Perspectives
Doru T. Alexandrescu et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Paolo A. Ascierto et al.
SEMINARS IN ONCOLOGY (2010)
Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
Margaret K. Callahan et al.
SEMINARS IN ONCOLOGY (2010)
Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
Tsvetelina Pentcheva-Hoang et al.
IMMUNOLOGICAL REVIEWS (2009)
Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy
John M. Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
Marianna Sabatino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Joseph F. Grosso et al.
JOURNAL OF IMMUNOLOGY (2009)
A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence
Kevin B. Kim et al.
MELANOMA RESEARCH (2009)
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors
Kavita V. Shah et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Interferon signaling and treatment outcome in chronic hepatitis C
Magdalena Sarasin-Filipowicz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients
Natalie J. Ives et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy
JH Zhou et al.
JOURNAL OF IMMUNOLOGY (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
JP Huang et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Transition of late-stage effector T cells to CD27(+) CD28(+) tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy
DJ Powell et al.
BLOOD (2005)
Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
PF Robbins et al.
JOURNAL OF IMMUNOLOGY (2004)
A review of recent findings involving interleukin-2-based cancer therapy
JW Eklund et al.
CURRENT OPINION IN ONCOLOGY (2004)
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
P Radny et al.
BRITISH JOURNAL OF CANCER (2003)
Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients
L Ridolfi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2001)
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance
H Nishimura et al.
TRENDS IN IMMUNOLOGY (2001)
Interleukin-2 in cancer therapy - Uses and optimum management of adverse effects
T Mekhail et al.
BIODRUGS (2000)
Distinct requirements for IFNs and STAT1 in NK cell function
CK Lee et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
